Innoviva Inc (INVA) Stock Price, Quote & News

Company Profile

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 238 9600

Website: www.inva.com

Address:

1350 Old Bayshore Highway, Suite 400, Burlingame, United States

StocktwitsEarnings Mar. 5 at 7:00 PM

$INVA Q4 '25 Earnings Results & Recap Innoviva reported total revenue of $411.3M for FY2025, with net product sales increasing 77% to $172.1M. Net income for Innoviva was $271.2M ($4.02 basic EPS).

0 · Reply

OfficialStocktwitsUser Mar. 3 at 1:31 PM

$INVA RSI: 61.95, MACD: 0.7736 Vol: 1.00, MA20: 22.64, MA50: 20.89 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

TheBehavioralTrader Feb. 26 at 7:57 PM

$INVA looks like normal profit taking to me I expect this to move back to 52-week highs.

0 · Reply

All4Retiring Feb. 26 at 5:05 PM

$INVA Link to Oppenheimer Fireside Chat today w CEO https://investor.inva.com/presentations-events

0 · Reply

All4Retiring Feb. 26 at 1:33 PM

$INVA https://www.stocktwits.com/symbol/INVA/companycall

0 · Reply

All4Retiring Feb. 25 at 10:59 PM

Investor Relations - Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress - Innoviva $INVA https://investor.inva.com/news-releases/news-release-details/innoviva-reports-fourth-quarter-and-full-year-2025-financial

0 · Reply

Itinerant Feb. 25 at 9:41 PM

$INVA This is a beautiful earnings report, thanks, in part to Armata.

1 · Reply

robber Feb. 25 at 9:05 PM

$INVA what ever happened to this selling with its royalties at one point? Anyone have any info?

0 · Reply

Rickycello Feb. 25 at 12:31 PM

$INVA bear: $18 base: $33 bull: $46 Intrinsic value: $26.72 Sell price target: $32.6 (28% margin) Reward / risk: 8.66 Risk / reward: 0.12

0 · Reply

BillionerOfKing Feb. 22 at 1:03 PM

$INVA Current Stock Price: $23.39 Contracts to trade: $22.5 INVA Mar 20 2026 Call Entry: $1.15 Exit: $1.50 ROI: 31% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report

Feb 27, 2026, 5:37 PM EST - 16 days ago

Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Feb 25, 2026, 4:05 PM EST - 18 days ago

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

Feb 19, 2026, 8:00 AM EST - 24 days ago

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Dec 12, 2025, 4:56 PM EST - 3 months ago

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

Dec 12, 2025, 1:33 PM EST - 3 months ago

US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections

Dec 11, 2025, 6:35 PM EST - 3 months ago

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

Nov 25, 2025, 7:00 AM EST - 3 months ago

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 5, 2025, 4:05 PM EST - 4 months ago

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Antheia Appoints Eric d'Esparbes as Chief Financial Officer

Oct 20, 2025, 8:00 AM EDT - 5 months ago

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Oct 7, 2025, 8:00 AM EDT - 5 months ago

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

Sep 2, 2025, 4:03 PM EDT - 6 months ago

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 7:00 AM EDT - 7 months ago

Innoviva to Participate in Upcoming Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 7 months ago

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

Aug 6, 2025, 4:05 PM EDT - 7 months ago

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

Jun 12, 2025, 7:00 AM EDT - 9 months ago

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Jun 10, 2025, 6:00 AM EDT - 9 months ago

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

May 20, 2025, 6:00 AM EDT - 10 months ago

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

May 20, 2025, 1:15 AM EDT - 10 months ago

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

May 7, 2025, 4:05 PM EDT - 11 months ago

Innoviva Reports First Quarter 2025 Financial Results; Highlights Recent Company Progress

Mar 12, 2025, 5:08 PM EDT - 1 year ago

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva

ARMP

Mar 5, 2025, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Barclays 27th Annual Global Healthcare Conference

Feb 26, 2025, 4:04 PM EST - 1 year ago

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Feb 23, 2025, 1:11 AM EST - 1 year ago

Innoviva: Underappreciated Strength In Hospital Therapeutics

Feb 6, 2025, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Dec 16, 2024, 7:00 AM EST - 1 year ago

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Dec 16, 2024, 1:15 AM EST - 1 year ago

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Nov 26, 2024, 7:00 AM EST - 1 year ago

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 1 year ago

Innoviva to Participate in the UBS Global Healthcare Conference

Nov 6, 2024, 4:05 PM EST - 1 year ago

Innoviva Reports Third Quarter 2024 Financial Results; Highlights Recent Company Progress

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress

Jun 18, 2024, 1:44 PM EDT - 1 year ago

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs

GSK

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 2 years ago

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 8, 2024, 7:00 AM EDT - 2 years ago

Innoviva to Participate in the BofA Securities Health Care Conference

Apr 24, 2024, 7:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

Mar 4, 2024, 4:01 PM EST - 2 years ago

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

ARMP

Feb 29, 2024, 4:05 PM EST - 2 years ago

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

Feb 28, 2024, 2:48 PM EST - 2 years ago

10 stocks you can bet on being inflation-proof

AM CW CXW HCC OTTR PCAR RDN

Nov 1, 2023, 4:15 PM EDT - 2 years ago

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023

Oct 9, 2023, 1:48 PM EDT - 2 years ago

Innoviva: A Lot Of Moving Parts

Sep 19, 2023, 8:30 AM EDT - 2 years ago

Innoviva to Participate in the Cantor Global Healthcare Conference

Sep 18, 2023, 8:00 AM EDT - 2 years ago

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

Aug 25, 2023, 4:52 PM EDT - 2 years ago

Innoviva Appoints Stephen Basso as Chief Financial Officer

Aug 2, 2023, 4:05 PM EDT - 2 years ago

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

StocktwitsEarnings Mar. 5 at 7:00 PM

$INVA Q4 '25 Earnings Results & Recap Innoviva reported total revenue of $411.3M for FY2025, with net product sales increasing 77% to $172.1M. Net income for Innoviva was $271.2M ($4.02 basic EPS).

0 · Reply

OfficialStocktwitsUser Mar. 3 at 1:31 PM

0 · Reply

TheBehavioralTrader Feb. 26 at 7:57 PM

$INVA looks like normal profit taking to me I expect this to move back to 52-week highs.

0 · Reply

All4Retiring Feb. 26 at 5:05 PM

$INVA Link to Oppenheimer Fireside Chat today w CEO https://investor.inva.com/presentations-events

0 · Reply

All4Retiring Feb. 26 at 1:33 PM

$INVA https://www.stocktwits.com/symbol/INVA/companycall

0 · Reply

All4Retiring Feb. 25 at 10:59 PM

0 · Reply

Itinerant Feb. 25 at 9:41 PM

$INVA This is a beautiful earnings report, thanks, in part to Armata.

1 · Reply

robber Feb. 25 at 9:05 PM

$INVA what ever happened to this selling with its royalties at one point? Anyone have any info?

0 · Reply

Rickycello Feb. 25 at 12:31 PM

$INVA bear: $18 base: $33 bull: $46 Intrinsic value: $26.72 Sell price target: $32.6 (28% margin) Reward / risk: 8.66 Risk / reward: 0.12

0 · Reply

BillionerOfKing Feb. 22 at 1:03 PM

0 · Reply

Itinerant Feb. 21 at 5:39 PM

$INVA I believe that INVA is under valued because historically the company has shown weak earnings growth, and the company's strong balance sheet is ignored by the market (a common cause of mis-valuation). Now, however, the market is expecting a strengthening in operating cash flow resulting from the newly approved drug. I expect this stock price trend to continue, unless the earnings expectations disappoint. The management of this company is very careful and conservative. You may recall that this company spun out Theravance BioPharma, which is an equally excellent company. I am long.

0 · Reply

Night_Owl_Biotech Feb. 18 at 3:10 AM

Commercial-stage bios trading near 4.5 highs since 10/1/2025. All 5 below trading at 4.5 month highs $GERN has been trading between $1.25 & $1.45 since April 2025, and after JPM. If anyone is aware why GERN is running please share. $TWST is way up consistently since 2/2/26 after big guidance for FY2026. $PGEN Consensus for Papzimeos as new first-line SOC for Papillomatosis per 1/20/26 PR $INVA There is no PR nor SEC filing since 12/25 outside of Nuzolvence approval $KNSA $900MM in FY26 product revenue guidance from $677 in FY25 (approval in 3/2021). Still trading at 4.0X FY2026 For entertainment purposes only.

1 · Reply

erevnon Feb. 17 at 12:07 PM

BTIG initiates coverage on Innoviva $INVA at Buy rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

BillionerOfKing Feb. 13 at 11:57 AM

$INVA Current Stock Price: $22.42 Contracts to trade: $22.5 INVA Feb 20 2026 Call Entry: $0.33 Exit: $0.51 ROI: 52% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

MktProfile Feb. 4 at 1:53 PM

$INVA is a pharmaceutical company focused on developing and commercializing hospital-based injectable drugs; it operates in a niche with moderate growth and faces pricing pressure.

0 · Reply

All4Retiring Jan. 29 at 5:28 PM

$INVA The Innoviva competitor is asking $89 per tablet for Blujepa and 8 tablets are required for gonorrhea. Innoviva’s Zoliflodacin only requires 1 tablet. A clear advantage.

0 · Reply

AeroSmith Jan. 22 at 4:49 PM

$INVA Two 57 cent Qs in a row. PE of 14. Forward PE of 9. Turning up.

0 · Reply

ninergizer Jan. 20 at 10:35 PM

$INVA been in consolidation and should be ready for a break out. let's go! : )😃

0 · Reply

Tomorrowscoin Jan. 15 at 9:11 PM

$INVA I think I have a glitch in my account 😳

0 · Reply

ninergizer Jan. 14 at 11:47 PM

$ARWR $MIST $INVA First five on my list was approved $ATRA had CRL, waiting game until buy out or a meeting with FDA as this was already approved in EU. I have my next top 10 PDUFA coming soon.

1 · Reply

TheologyTinge Dec. 27 at 4:25 PM

$INVA Market participants want evidence that strategy converts to numbers; unit economics must show steady improvement — improving transparency could compress perceived risk. Execution quality is likely to be the main catalyst.

0 · Reply

Revaluation Dec. 26 at 3:55 PM

$INVA Considering entry here, anyone know why income is trending down so badly?

0 · Reply

Market Cap	1.63B
Revenue (ttm)	411.33M
Net Income (ttm)	271.17M
EPS (ttm)	N/A
PE Ratio	5.45
Forward PE	11.04
Profit Margin	65.93%
Debt to Equity Ratio	0.22

Volume	650,000
Avg Vol	732,884
Day's Range	N/A - N/A
Shares Out	74.07M
Stochastic %K	29%
Beta	0.42
Analysts	Sell
Price Target	$33.20